This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction The guidelines' recommendations for anticoagulation in cancer patients with catheter-related thrombosis are unclear. The aim of this systematic review was to assess anticoagulation management in cancer patients with catheter-related thrombosis (CRT) based on previously published studies.
BackgroundArterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.
Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism, based on findings from the API-CAT trial presented at ACC.25
To assess the effectiveness and safety profiles of rivaroxaban compared to low molecular weight heparin (LMWH) in managing lower extremity deep vein thrombosis (DVT) subsequent to thoracoscopic lung cancer sur.
Venous thromboembolism is a common complication of cancer and its treatments, and the incidence of recurrent thrombosis, serious bleeding, and death is higher among patients with this condition than in the general population. More than 20 years have passed since Lee et al.1 1 reported the results of the.
Active cancer is a strong risk factor for venous thromboembolism (VTE) events and recurrent events following discontinuation of anticoagulation therapy, and cancer patients are also at a heightened risk for bleeding complications related to anticoagulation treatment.
Phlegmasia cerulea dolens (PCD) is a rare yet severe complication of deep vein thrombosis (DVT), characterized by a high amputation rate and mortality. Early diagnosis and treatment are crucial in managing this condition. PCD predominantly affects the lower extremities rather than the upper extremities.
Objective This study aims to explore the effects of the Information-Motivation-Behavioral (IMB) Skills Model on the prevention of Venous Thromboembolism (VTE) in elderly lung cancer patients. After three months of intervention, the hospital satisfaction and VTE incidence rates in both groups were investigated and compared.
IntroductionCerebral venous sinus thrombosis (CVST) is a rare form of stroke that usually affects young females especially during pregnancy and the postpartum period. The symptoms of cerebral venous sinus thrombosis can vary depending on the location and extent of the clot.
Background:Information on long-term care utilization patterns following the acute care period of cerebral venous thrombosis (CVT) is limited. Cancer-related CVT was associated with a higher rate of readmission (p<0.0001) and traumatic CVT was associated with a lower rate (p=0.005). years (SD 19). years (95% CI 1.4-2.4),
Abelacimab is currently in Phase 3 development with the lead indication for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026.
Age, proximal and distal deep vein thrombosis (DVT) vs. distal DVT, active cancer, history of long-term immobilization, VTE was detected in the intensive care unit, active/recurrent bleeding, IVC thrombosis, and history of venous thromboembolism were independent predictive risk factors for non-retrieval of filters.
Background Left atrial (LA) hemodynamics after lung lobectomies with pulmonary vein (PV) resection is widely understood to be a risk factor for LA thrombosis. Methods The computational simulations of LA blood flow were conducted on the basis of four-dimensional computed tomography images of four lung cancer patients prior to lobectomies.
Harvard University Heart Letter) A clinical polygenic risk score test for diseases ranging from atrial fibrillation (AFib) to breast cancer was piloted by scientists. Avocado consumption of at least two servings per week is linked to a lower risk of cardiovascular disease.
Background and Objectives:Understanding the mechanisms of thrombosis is crucial for the future advancement in treating ischemic stroke. After adjusting for potential confounders including posterior circulation occlusion, serum hemoglobin levels, serum albumin levels, and the presence of active cancer (all p<0.05
Introduction:Active cancer is a known risk factor for cerebral venous thrombosis (CVT), but it is unknown whether CVT is also associated with occult cancer. Patients with a history of cancer and patients diagnosed with cancer during admission for the index CVT were excluded. after 10 years. at 1 year and 1.4 [1.1-1.7]
The composition of thrombi may reflect the mechanism of thrombosis, aiding the determination of the treatment strategy. Platelet composition was significantly higher in the cancer group than in the control group (median [interquartile range], 51.3% [28.0%–61.4%] 61.4%] versus 9.5% [4.8%–14.0%];P<0.001). 14.0%];P<0.001).
IntroductionCerebral Venous Thrombosis (CVT) is a rare cerebrovascular condition causing death or functional dependency in 10‐15%. 0.48, p=0.001), CNS cancer (OR: 0.24, 95% CI: 0.06‐0.93, 0.93, p=0.039), other types of cancer (OR: 0.47, 95% CI: 0.32‐0.69, 2.67, p<0.001), seizure (OR: 1.54, 95% CI: 1.09‐2.16,
Background and Purpose:Cancer increases the risk for acute ischemic stroke (AIS) and deep venous thrombosis. The role of paradoxical embolization as a stroke etiology in patients with cancer is uncertain. Our study investigated the relationship between cancer-related stroke and the presence of a patent foramen ovale (PFO).Methods:We
Subsequent investigations revealed pulmonary embolism, deep vein thrombosis, and imaging findings suggestive of pancreatic cancer. Following PCI, she was treated with optimal medical therapy, including dual antiplatelet therapy. Anticoagulation therapy was initiated to manage the VTE.
Deep Vein Thrombosis (DVT) : A blood clot occurring in a deep vein. Causes include infection, malignancy, surgery, scar tissue formation, trauma, deep vein thrombosis (DVT), radiation or other cancer treatment. Damaged valves within the veins cause this.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content